Allergy Territory Account Specialist

Quote
anonymous said:
passed over?, lol....ABL’s haven’t even been contacted yet, you dolt....but thanks for letting us all know you have zero clue and have certainly not been offered anything. I guess your 6 months comment could be correct, especially from someone coming from CRM and that tragic launch. Hell, I’d be looking for ANY life raft to cling onto as well...good luck, “son”.
Click to expand...

Remi will make a difference for the patient, clinical trial participants beg to be kept on drug at least in urticaria. Would expect even more job offers to cover all the potential 6 months after launch. And experience or established relations are almost not necessary due to market pull. And former CRM colleagues are appreciated, Kounis syndrome could also be solved by Remi ;-)
 




anonymous said:
Actually hiring for new build out sales forces in Pharma nowadays is a good 80% networking via contacts and who you know. You sound like an old mental stooge who is stuck in the past from 15-20 years ago. Dummy
Click to expand...

I’m a dummy, really? No, I’m someone that believes people should be hired and promoted based on merit and accomplishment. Unlike your dumb A that is probably always looking for your new job, 3 months into your current job. That way you never really have to succeed or fail, you just kind of fly under the radar, devoid of any accomplishment and most likely a pathetic track record. Your survival is solely based on your disgusting brown nosing skills at regional and national sales meetings that most of us having been rolling our eyes at for decades. And just a hunch, I’m guessing you’re also probably one of those parasites that milk the system every 12-18 months with some sort of extended illness or disability. Yeah, we all know the type, and I’m sure you’re one. So take it from an “old stooge”, piss off you pathetic bottom dweller and remember to thank the good lord on a daily basis you found and industry where a no talent, ass kiss like yourself can survive and earn a good living.
 




anonymous said:
No, interviews have not started for the TAS role. They posted all of the jobs too early because they were trying to get ahead of everything moving over to Workday in March. They are hiring from the top down. ED, RD, ABL, then TAS. From what I heard, they are currently working on the ABLs right now. They will likely start reaching out to internal candidates to set up interviews in early June. Aiming to have people in the field by early August.
Click to expand...
So potentially TAS offers out in July?
 




anonymous said:
Damn pops for somebody retired you are a waste of space trolling pharma jobs sites offering your dated opinions. No outside interest or hobbies eh loser? I feel sorry for you…… and that being truthful.
Click to expand...

again, thought you beat it clown? I’ve noticed one thing about your pathetic generation that I find interesting. You guys can’t do much, but you do like to get the last word for some reason, so I guess you get some points for tenacity....Hit me up after your 5 minute You Porn session this afternoon....but before your wasted 3 hours on Tik Tok, before you cry yourself to sleep....bahahahahahaha
 




anonymous said:
again, thought you beat it clown? I’ve noticed one thing about your pathetic generation that I find interesting. You guys can’t do much, but you do like to get the last word for some reason, so I guess you get some points for tenacity....Hit me up after your 5 minute You Porn session this afternoon....but before your wasted 3 hours on Tik Tok, before you cry yourself to sleep....bahahahahahaha
Click to expand...
“bahahahahahaha”…….. another dated phrase gramps from over 10 years ago. Do yourself a favor and go find a better way to spend your retirement ya dumb old man. I feel sorry for you.
 




anonymous said:
I’m a dummy, really? No, I’m someone that believes people should be hired and promoted based on merit and accomplishment. Unlike your dumb A that is probably always looking for your new job, 3 months into your current job. That way you never really have to succeed or fail, you just kind of fly under the radar, devoid of any accomplishment and most likely a pathetic track record. Your survival is solely based on your disgusting brown nosing skills at regional and national sales meetings that most of us having been rolling our eyes at for decades. And just a hunch, I’m guessing you’re also probably one of those parasites that milk the system every 12-18 months with some sort of extended illness or disability. Yeah, we all know the type, and I’m sure you’re one. So take it from an “old stooge”, piss off you pathetic bottom dweller and remember to thank the good lord on a daily basis you found and industry where a no talent, ass kiss like yourself can survive and earn a good living.
Click to expand...

Great message! Us old timers also have the pension which the younger pepole envy.
 




anonymous said:
“bahahahahahaha”…….. another dated phrase gramps from over 10 years ago. Do yourself a favor and go find a better way to spend your retirement ya dumb old man. I feel sorry for you.
Click to expand...

what is bahahahah?

Are you a sheep or a goat?

You can start your evolution by turning off your television set, where you get most of your information on how to live.

Then, you can learn the alphabet. Its starts with an A and ends with a Z.

Good luck. Keep us posted.

If you need any help getting through your core visual aid, then call your manager and you can role play on the phone or just ask a peer mate (my guess is that you are a career pod seller) to come over with some beers (I assume you are an alcoholic), and you can have a blast with the graphs and stuff you all come up with to sell your garbage, overpriced products.

Cheers mate ! Happy Memorial Day weekend!
 




anonymous said:
what is bahahahah?

Are you a sheep or a goat?

You can start your evolution by turning off your television set, where you get most of your information on how to live.

Then, you can learn the alphabet. Its starts with an A and ends with a Z.

Good luck. Keep us posted.

If you need any help getting through your core visual aid, then call your manager and you can role play on the phone or just ask a peer mate (my guess is that you are a career pod seller) to come over with some beers (I assume you are an alcoholic), and you can have a blast with the graphs and stuff you all come up with to sell your garbage, overpriced products.

Cheers mate ! Happy Memorial Day weekend!
Click to expand...


It’s nice of you to wish them a happy memorial day, but sadly they probably have no real understanding of what memorial day is about. The reality is there are a lot of people that died tin the efforts To keep our country in attack and alive. These dumb ass motherfuckers have no idea what that actually means.
 








what is bahahahah? -quote

Are you a sheep or a goat? - quote


Eh gramps….. people want to know about your dated phrases you keep throwing up. You are a pathetic example of how to spend life after retirement. Poor lonely bastard.
 








Novartis Compensation and Benefit Summary: The pay range for this position at commencement of employment is expected to be between:

Territory Account Specialist: $102,400 and $153,000/year |
Senior Territory Account Specialist: $124,000 and $186,000/year |
Executive Territory Account Specialist: $136,800 and $205,200/year; however, while salary ranges are effective from 1/1/24 through 12/31/24, fluctuations in the job market may necessitate adjustments to pay ranges during this period.

Further, final pay determinations will depend on various factors, including, but not limited to geographical location, experience level, knowledge, skills, and abilities. The total compensation package for this position may also include other elements, including a sign-on bonus, restricted stock units, and discretionary awards in addition to a full range of medical, financial, and/or other benefits (including 401(k) eligibility and various paid time off benefits, such as vacation, sick time, and parental leave), dependent on the position offered. Details of participation in these benefit plans will be provided if an employee receives an offer of employment. If hired, employee will be in an “at-will position” and the Company reserves the right to modify base salary (as well as any other discretionary payment or compensation program) at any time, including for reasons related to individual performance, Company or individual department/team performance, and market factors.
 








Novartis cues up filings for remibrutinib in chronic hives

Novartis is just months away from filing for approval of oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria – also known as chronic hives – after reporting long-term data from two phase 3 trials.

12-week data from the REMIX-1 and REMIX-2 studies was reported last year, and Novartis now has the results for 52 weeks of follow-up, which it says confirms that the safety and efficacy of the drug in CSU is maintained over that period.

CSU affects around 1% of the global population and in severe cases causes itching and swelling that can last for weeks at a time and resist even very high doses of antihistamines, which are the first-line therapy of choice, but don’t work around 60% of the time.

Novartis estimates that there are around 400,000 people with uncontrolled CSU in the US alone. It is enormously debilitating, with almost two-thirds of patients experiencing mental health disorders, including depression and anxiety.

The phase 3 trials involved patients with CSU who remained symptomatic despite antihistamine treatment, comparing 25mg remibrutinib twice daily to placebo. After 24 weeks, patients in the placebo group were switched to the BTK inhibitor.

At 52 weeks, remibrutinib showed significant improvements in weekly urticaria activity score (UAS7), weekly itch severity score (ISS7), and weekly hive severity score (HSS7), with almost half of patients completely free of itch and hives - a UAS7 score of zero - at the end of the follow-up period.

Novartis’ anti-IgE antibody Xolair (omalizumab) has been a mainstay of treatment for refractory CSU for many years. However, the drug is heading for patent expiry in Europe this year and in the US in 2025, so the company has been looking for a successor for some time.

Its first attempt was a follow-up IgE inhibitor called ligelizumab, which was dropped for CSU, but remains in testing for food allergies – an indication for which Xolair was approved in February by the FDA.

Novartis had been holding off on filing remibrutinib until the 52-week data came in, and has now said it will move ahead with filing the drug for CSU with global regulatory authorities in the second half of this year.

It is also resting remibrutinib in phase 3 trials for chronic inducible urticaria (CINDU) and multiple sclerosis (MS), and in phase 2 for hidradenitis suppurativa (HS) and food allergy.

Analysts have suggested that approval in CSU alone could make it a blockbuster, with sales of more than $1 billion.

It could see competition from Sanofi and Regeneron’s IL-4 and IL-13 inhibitor Dupixent (dupilumab) – already a $12 billion blockbuster in other indications – as well as Sanofi’s rival oral BTK inhibitor rilzabrutinib, which showed promise in a mid-stage trial and is heading for phase 3 trials this year.

Dupixent was rejected by the FDA for CSU last October with a request for more efficacy data, but has been approved for that indication in Japan and is also under review in Europe.
 
















anonymous said:
today they predicted 14 billion annual peak sales for the near term immunology portfolio...
Click to expand...
With Entresto pretty much finished, Leqvio unlikely to return half it's investment, and an Lp(A) niche product, it wouldn't come as a complete shock if Novartis just spun off Cardio for pennies on the dollar in 2027.
Unless something changes in rather dramatic fashion, there isn't much of a future for Cardiology here.
 












Top Bottom
Back
Quote